-
2
-
-
2642551603
-
Development of the proteasome inhibitor Velcade (Bortezomib)
-
Adams, J.; Kauffman, M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 2004, 22, 304-311.
-
(2004)
Cancer Invest
, vol.22
, pp. 304-311
-
-
Adams, J.1
Kauffman, M.2
-
3
-
-
0036240701
-
The proteasome: A novel target for cancer chemotherapy
-
Almond, J.B.; Cohen, G.M. The proteasome: A novel target for cancer chemotherapy. Leukemia 2002, 16, 433-443.
-
(2002)
Leukemia
, vol.16
, pp. 433-443
-
-
Almond, J.B.1
Cohen, G.M.2
-
4
-
-
0036690648
-
PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis
-
Ling, Y.H.; Liebes, L.; Ng, B.; Buckley, M.; Elliott, P.J.; Adams, J.; Jiang, J.D.; Muggia, F.M.; Perez-Soler, R. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol. Cancer Ther. 2002, 1, 841-849.
-
(2002)
Mol. Cancer Ther
, vol.1
, pp. 841-849
-
-
Ling, Y.H.1
Liebes, L.2
Ng, B.3
Buckley, M.4
Elliott, P.J.5
Adams, J.6
Jiang, J.D.7
Muggia, F.M.8
Perez-Soler, R.9
-
5
-
-
0242468166
-
Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent process
-
Dai, Y.; Rahmani, M.; Grant, S. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent process. Oncogene 2003, 22, 7108-7122.
-
(2003)
Oncogene
, vol.22
, pp. 7108-7122
-
-
Dai, Y.1
Rahmani, M.2
Grant, S.3
-
6
-
-
70450227260
-
Proteasome inhibitors in the treatment of multiple myeloma
-
Shah, J.J.; Orlowski, R.Z. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 2009, 23, 1964-1979.
-
(2009)
Leukemia
, vol.23
, pp. 1964-1979
-
-
Shah, J.J.1
Orlowski, R.Z.2
-
7
-
-
0038473927
-
Flavopiridol in untreated or relapsed mantle-cell lymphoma: Results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group
-
Kouroukis, C.T.; Belch, A.; Crump, M.; Eisenhauer, E.; Gascoyne, R.D.; Meyer, R.; Lohmann, R.; Lopez, P.; Powers, J.; Turner, R., et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: Results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2003, 21, 1740-1745.
-
(2003)
J. Clin. Oncol
, vol.21
, pp. 1740-1745
-
-
Kouroukis, C.T.1
Belch, A.2
Crump, M.3
Eisenhauer, E.4
Gascoyne, R.D.5
Meyer, R.6
Lohmann, R.7
Lopez, P.8
Powers, J.9
Turner, R.10
-
8
-
-
80053196640
-
Combining proteasome with cell cycle inhibitors: A dual attack potentially applicable to multiple hematopoietic malignancies
-
Holkova, B.; Grant, S. Combining proteasome with cell cycle inhibitors: A dual attack potentially applicable to multiple hematopoietic malignancies. Expert Rev. Hematol. 2011, 4, 483-486.
-
(2011)
Expert Rev. Hematol
, vol.4
, pp. 483-486
-
-
Holkova, B.1
Grant, S.2
-
9
-
-
0028867742
-
Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane)
-
Singh, S.; Aggarwal, B.B. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). J. Biol. Chem. 1995, 270, 24995-25000.
-
(1995)
J. Biol. Chem
, vol.270
, pp. 24995-25000
-
-
Singh, S.1
Aggarwal, B.B.2
-
10
-
-
55749098119
-
Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines
-
Hussain, A.R.; Ahmed, M.; Al-Jomah, N.A.; Khan, A.S.; Manogaran, P.; Sultana, M.; Abubaker, J.; Platanias, L.C.; Al-Kuraya, K.S.; Uddin, S. Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol. Cancer Ther. 2008, 7, 3318-3329.
-
(2008)
Mol. Cancer Ther
, vol.7
, pp. 3318-3329
-
-
Hussain, A.R.1
Ahmed, M.2
Al-Jomah, N.A.3
Khan, A.S.4
Manogaran, P.5
Sultana, M.6
Abubaker, J.7
Platanias, L.C.8
Al-Kuraya, K.S.9
Uddin, S.10
-
11
-
-
84859047406
-
BDMC33, a curcumin derivative suppresses inflammatory responses in macrophage-like cellular system: Role of inhibition in NF-κB and MAPK signaling pathways
-
Lee, K.H.; Chow, Y.L.; Sharmili, V.; Abas, F.; Alitheen, N.B.M.; Shaari, K.; Israf, D.A.; Lajis, N.H.; Syahida, A. BDMC33, a curcumin derivative suppresses inflammatory responses in macrophage-like cellular system: Role of inhibition in NF-κB and MAPK signaling pathways. Int. J. Mol. Sci. 2012, 13, 2985-3008.
-
(2012)
Int. J. Mol. Sci
, vol.13
, pp. 2985-3008
-
-
Lee, K.H.1
Chow, Y.L.2
Sharmili, V.3
Abas, F.4
Alitheen, N.B.M.5
Shaari, K.6
Israf, D.A.7
Lajis, N.H.8
Syahida, A.9
-
12
-
-
36849018017
-
Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R
-
Patel, B.B.; Sengupta, R.; Qazi, S.; Vachhani, H.; Yu, Y.; Rishi, A.K.; Majumdar, A.P. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int. J. Cancer 2008, 122, 267-273.
-
(2008)
Int. J. Cancer
, vol.122
, pp. 267-273
-
-
Patel, B.B.1
Sengupta, R.2
Qazi, S.3
Vachhani, H.4
Yu, Y.5
Rishi, A.K.6
Majumdar, A.P.7
-
13
-
-
27144468987
-
Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice
-
Aggarwal, B.B.; Shishodia, S.; Takada, Y.; Banerjee, S.; Newman, R.A.; Bueso-Ramos, C.E.; Price, J.E. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin. Cancer Res. 2005, 11, 7490-7498.
-
(2005)
Clin. Cancer Res
, vol.11
, pp. 7490-7498
-
-
Aggarwal, B.B.1
Shishodia, S.2
Takada, Y.3
Banerjee, S.4
Newman, R.A.5
Bueso-Ramos, C.E.6
Price, J.E.7
-
14
-
-
66449104640
-
Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model
-
Sung, B.; Kunnumakkara, A.B.; Sethi, G.; Anand, P.; Guha, S.; Aggarwal, B.B. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol. Cancer Ther. 2009, 8, 959-970.
-
(2009)
Mol. Cancer Ther
, vol.8
, pp. 959-970
-
-
Sung, B.1
Kunnumakkara, A.B.2
Sethi, G.3
Anand, P.4
Guha, S.5
Aggarwal, B.B.6
-
15
-
-
56349157010
-
Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells
-
Park, J.; Ayyappan, V.; Bae, E.K.; Lee, C.; Kim, B.S.; Kim, B.K.; Lee, Y.Y.; Ahn, K.S.; Yoon, S.S. Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells. Mol. Oncol. 2008, 2, 317-326.
-
(2008)
Mol. Oncol
, vol.2
, pp. 317-326
-
-
Park, J.1
Ayyappan, V.2
Bae, E.K.3
Lee, C.4
Kim, B.S.5
Kim, B.K.6
Lee, Y.Y.7
Ahn, K.S.8
Yoon, S.S.9
-
16
-
-
84862832998
-
Effect of curcumin in combination with bortezomib on proliferation and apoptosis of human multiple myeloma cell line H929 and its mechanism
-
Zhang, X.Y.; Bai, Q.X.; Huang, G.S.; Zhao, H.; Chen, J.J.; Yang, L.J. Effect of curcumin in combination with bortezomib on proliferation and apoptosis of human multiple myeloma cell line H929 and its mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2011, 19, 684-688.
-
(2011)
Zhongguo Shi Yan Xue Ye Xue Za Zhi
, vol.19
, pp. 684-688
-
-
Zhang, X.Y.1
Bai, Q.X.2
Huang, G.S.3
Zhao, H.4
Chen, J.J.5
Yang, L.J.6
-
17
-
-
84855162753
-
Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs
-
Mujtaba, T.; Kanwar, J.; Wan, S.B.; Chan, T.H.; Dou, Q.P. Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs. Int. J. Mol. Med. 2012, 29, 102-106.
-
(2012)
Int. J. Mol. Med
, vol.29
, pp. 102-106
-
-
Mujtaba, T.1
Kanwar, J.2
Wan, S.B.3
Chan, T.H.4
Dou, Q.P.5
-
18
-
-
78650371990
-
MCP-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NF-κB signaling
-
Liang, J.; Saad, Y.; Lei, T.; Wang, J.; Qi, D.; Yang, Q.; Kolattukudy, P.E.; Fu, M. MCP-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NF-κB signaling. J. Exp. Med. 2010, 207, 2959-2973.
-
(2010)
J. Exp. Med
, vol.207
, pp. 2959-2973
-
-
Liang, J.1
Saad, Y.2
Lei, T.3
Wang, J.4
Qi, D.5
Yang, Q.6
Kolattukudy, P.E.7
Fu, M.8
-
19
-
-
79955665002
-
Aciculatin inhibits lipopolysaccharide-mediated inducible nitric oxide synthase and cyclooxygenase-2 expression via suppressing NF-κB and JNK/p38 MAPK activation pathways
-
doi:10.1186/1423-0127-18-28
-
Hsieh, I.N.; Chang, A.S.; Teng, C.M.; Chen, C.C.; Yang, C.R. Aciculatin inhibits lipopolysaccharide-mediated inducible nitric oxide synthase and cyclooxygenase-2 expression via suppressing NF-κB and JNK/p38 MAPK activation pathways. J. Biomed. Sci. 2011, 18, doi:10.1186/1423-0127-18-28.
-
(2011)
J. Biomed. Sci
, pp. 18
-
-
Hsieh, I.N.1
Chang, A.S.2
Teng, C.M.3
Chen, C.C.4
Yang, C.R.5
|